Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rezafungin acetate - Cidara Therapeutics

Next Previous
Drug Profile

Rezafungin acetate - Cidara Therapeutics

Alternative Names: Biafungin; CD 101; CD 101 IV; CD 101 Topical; Rezafungin; Rezafungin acetate; REZZAYO; Rezzayo; SP-3025

Latest Information Update: 02 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Seachaid Pharmaceuticals
  • Developer Cidara Therapeutics; Mundipharma International
  • Class Acetates; Amides; Antifungals; Aza compounds; Echinocandins; Phenols; Phenyl ethers; Small molecules
  • Mechanism of Action Glucan synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Invasive candidiasis; Candidiasis; Candidaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Candidaemia; Invasive candidiasis
  • Phase III Mycoses
  • Phase II Pneumocystis pneumonia
  • Discontinued Aspergillosis; Vulvovaginal candidiasis

Most Recent Events

  • 29 Jan 2024 Registered for Invasive candidiasis (In adults) in United Kingdom (IV)
  • 22 Dec 2023 Registered for Invasive candidiasis (In adults) in European Union (IV)
  • 22 Dec 2023 Registered for Invasive candidiasis (In adults) in Iceland (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top